Summary
Objective This survey aims at estimating the prevalence of SARS-CoV-2 in high risk populations in Lomé.
Methods From April 23rd to May 8th 2020, we recruited a random sample of participants from five sectors: healthcare, air transport, police, road transport and informal. We collected oropharyngeal swab for direct detection through real time reverse transcription polymerase chain reaction (rRT-PCR), and blood for antibodies detection by serological tests. The overall prevalence (current and past) of infection was defined by positivity for both tests.
Results A total of 955 participants with a median age of 36 (IQR 32-43) were included and 71.6% (n=684) were men. Around 22.1% (n=212) were from the air transport sector, 20.5% (n=196) in the police, and 38.7% (n=370) in the health sector. Seven participants (0.7%, 95% CI: 0.3-1.6%) had a positive rRT-PCR at the time of recruitment and nine (0.9%, 95% CI: 0.4-1.8%) were seropositive for IgM or IgG against SARS-CoV-2. We found an overall prevalence of 1.6% (n=15), 95% CI: 0.9-2.6%.
Conclusion The prevalence of the SARS-CoV-2 infection among high-risk populations in Lomé was relatively low and could be explained by the various measures taken by the Togolese government. Therefore, we recommend targeted screening.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Bioethics Committee for Health Research from the Togo Ministry of Health (No. 004/2020/CBRS)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Authors details WAH: hjacky78{at}yahoo.fr, YRK: rodionko{at}yahoo.fr, FAGK: fifonsi.gbeasor{at}gmail.com, AJS: sadioarnorld{at}gmail.com, MKT: tchankonimartin{at}yahoo.fr, KSK: komlanvikoffi{at}yahoo.fr, MS: mounerous{at}gmail.com, AMD: monicadork{at}yahoo.fr, IM: mamanissaka{at}yahoo.fr, AA: mag1.tg{at}gmail.com, MIW: majeste7{at}yahoo.fr, KSA: komiadjoh{at}yahoo.fr, EGA: edemcardiol{at}yahoo.fr, YK: yemblak{at}gmail.com, IK: ikpeto{at}gmail.com, PP: assimawepaul{at}gmail.com, RKS: kinderebecca{at}yahoo.fr, AT: stanrameklo{at}yahoo.fr, JNA: jyda45{at}hotmail.com, SHA: simpassane{at}yahoo.fr, MPD: mireilleprincedavid{at}gmail.com, SMA: awoussi{at}yahoo.com, MD: m_djibril2000{at}yahoo.fr, MM: moustafa.mijiyawa{at}gouv.tg, ACD: claverdagnra{at}gmail.com, DKE: didier.ekouevi{at}gmail.com
Data Availability
Data are available on request by sending an email to authors.
List of abbreviations
- 95% CI
- 95% confidence interval
- IQR
- interquartile range
